Fluzone® Intradermal vaccine: A promising new chance to increase the acceptability of influenza vaccination in adults

Expert Review of Vaccines

Volumn 11, Issue 1, 2012, Pages 17-25

  Ansaldi, Filippo ^a   De Florentiis, Daniela ^a   Durando, Paolo ^a   Icardi, Giancarlo ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

adult; dose sparing; immunogenicity; influenza vaccine; intradermal; safety

Indexed keywords

INFLUENZA VACCINE;

DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; ECCHYMOSIS; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; MALAISE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SHIVERING; TREATMENT RESPONSE;

ADOLESCENT; ADULT; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; INJECTIONS, INTRADERMAL; LICENSURE; MICROINJECTIONS; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; YOUNG ADULT;

EID: 83155164584     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.154     Document Type: Review

References (45)

1. Thompson WW, Shay DK, Weintraub E et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289, 179-186 (2003). (Pubitemid 36068705)
2. Monto AS, Ansaldi F, Aspinall R et al. Influenza control in the 21st century: optimizing protection of older adults. Vaccine 27(37), 5043-5053 (2009).
3. Dao CN, Kamimoto L, Nowell M et al. Adult hospitalizations for laboratory-positive influenza during the 2005-2006 through 2007-2008 seasons in the United States. J. Infect. Dis. 202, 881-888 (2010).
4. Thompson WW, Shay DK, Weintraub E et al. Influenza-associated hospitalizations in the United States. JAMA 292, 1333-1340 (2004). (Pubitemid 39223224)
5. Ryan J, Zoellner Y, Gradl B, Palache B, Medema J. Establishing the health and economic impact of influenza vaccination within the European Union 25 countries. Vaccine 24, 6812-6822 (2006). (Pubitemid 46137928)
6. Szucs T. The socio-economic burden of influenza. J. Antimicrob. Chemother. 44, 11-15 (1999). (Pubitemid 29531319)
7. Molinari NA, Ortega-Sanchez IR, Messonnier ML et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 25, 5086-5096 (2007). (Pubitemid 46879994)
8. Stinchfield PK. Practice-proven interventions to increase vaccination rates and broaden the immunization season. Am. J. Med. 121, S11-S21 (2008). (Pubitemid 351876194)
9. Fiore AE, Uyeki TM, Broder K et al. Centers for disease control and prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on immunization practices (ACIP). MMWR Recomm. Rep. 6, 59(RR-8), 1-62 (2010).
10. Muller D, Szucs TD. Influenza vaccination coverage rates in 5 European countries: a population-based cross-sectional analysis of the seasons 02/03, 03/04 and 04/05. Infection 35, 308-319 (2007). (Pubitemid 47502348)
11. Hollmeyer HG, Hayden F, Poland G, Buchholz U. Influenza vaccination of health care workers in hospitals - a review of studies on attitudes and predictors. Vaccine 27, 3935-3944 (2009).
12. Keeton VF, Chen AK. Immunization updates and challenges. Curr. Opin. Pediatr. 22, 234-240 (2010).
13. Evison J, Farese S, Seitz M et al. Randomized, double-blind comparative trial of subunit and virosomal influenza vaccines for immunocompromised patients. Clin. Infect. Dis. 48(10), 1402-1412 (2009).
14. de Bruijn IA, Nauta J, Gerez L et al. The virosomal influenza vaccine Invivac: immunogenicity and tolerability compared to an adjuvanted influenza vaccine (Fluad in elderly subjects. Vaccine 24(44-46), 6629-6631 (2006). (Pubitemid 46107151)
15. Baldo V, Menegon T, Bonello C et al. Comparison of three different influenza vaccines in institutionalised elderly. Vaccine 19(25-26), 3472-3475 (2001). (Pubitemid 32710298)
16. Pregliasco F, Mensi C, Serpilli W et al. Immunogenicity and safety of three commercial influenza vaccines in institutionalized elderly. Aging 13(1), 38-43 (2001). (Pubitemid 32241877)
17. Weller TH, Cheever FS, Enders JF. Immunologic reactions following intradermal inoculation of influenza A and B vaccine. Proc. Soc. Exp. Biol. Med. 67, 96-101 (1948).
18. Lenz A, Heine M, Schuler G, Romani N. Human and murine dermis contain dendritic cells. Isolation by means of a novel method and phenotypical and functional characterization. J. Clin. Invest. 92, 2587-2596 (1993). (Pubitemid 24006521)
19. Nestle FO, Zheng XG, Thompson CB, Turka LA, Nickoloff BJ. Characterization of dermal dendritic cells obtained from normal human skin reveals phenotypic and functionally distinctive subsets. J. Immunol. 1, 151(11), 6535-6545 (1993). Erratum in: J. Immunol. 152(1), 376 (1994). (Pubitemid 23340400)
20. Spellberg B. The cutaneous citadel. A holistic view of skin and immunity. Life Sci. 67, 477-502 (2000). (Pubitemid 30431538)
21. Briggs DJ, Banzhoff A, Nicola U et al. Antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick embrio cell vaccine or purified verocell rabies vaccine. Bull. World Health Organ. 78, 693-698 (2000). (Pubitemid 30398852)
22. Bryan JP, Sjogren MH, Perine PL, Legters LJ. Low-dose intradermal and intramuscolar vaccination against hepatitis B. Clin. Infect. Dis. 14, 697-707 (1992).
23. Redfield RR, Innis BL, Scott RM, Cannon HG, Bancroft WH. Clinical evaluation of low-dose intradermally administered hepatitis B virus vaccine. A cost reduction strategy. JAMA 254(22), 3203-3206 (1985). (Pubitemid 16206972)
24. Nicolas JF, Guy B. Intradermal, epidermal and transcutaneous vaccination: from immunology to clinical practice. Expert Rev. Vaccines 7, 1201-1214 (2008).
25. Belshe RB, Newman FK, Cannon J et al. Serum antibody responses after intradermal vaccination against influenza. N. Engl. J. Med. 351, 2286-2294 (2004). (Pubitemid 39552744)
26. Belshe RB, Newman FK, Wilkins K, Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults. Vaccine 25, 6755-6763 (2007). (Pubitemid 47332726)
27. Burland WL. Measles vaccination by the intradermal route. Postgrad. Med. J. 45(523), 323-326 (1969).
28. Zoulek G, Roggendorf M, Deinhardt F, Kunz C. Different immune responses after intradermal and intramuscular administration of vaccine against tick-borne encephalitis virus. J. Med. Virol. 19(1), 55-61 (1986). (Pubitemid 16142972)
29. Roukens AH, Vossen AC, Bredenbeek PJ, van Dissel JT, Visser LG. Intradermally administered yellow fever vaccine at reduced dose induces a protective immune response: a randomized controlled non-inferiority trial. PLoS One 3(4), e1993 (2008).
30. Nelson R. Influenza vaccine shortage hits the USA. Lancet 362, 2075 (2004).
31. Partridge J, Kieny MP. World Health Organization H1N1 influenza vaccine task force. Global production of seasonal and pandemic (H1N1) influenza vaccines in 2009-2010 and comparison with previous estimates and global action plan targets. Vaccine 28(30), 4709-4712 (2010).
32. Hessel L. European vaccine manufacturers (EVM) influenza working group. Pandemic influenza vaccines: meeting the supply, distribution and deployment challenges. Influenza Other Respi. Virus 3(4), 165-170 (2009).
33. Lambert PH, Laurent PE. Intradermal vaccine delivery: will new delivery systems transform vaccine administration? Vaccine 26, 3197-3208 (2008).
34. Leroux-Roels I, Vets E, Freese R et al. Seasonal influenza vaccine delivered by intradermal microinjection: a randomized controlled safety and immunogenicity trial in adults. Vaccine 26, 6614-6619 (2008).
35. Beran J, Ambrozaitis A, Laiskonis A et al. Intradermal influenza vaccination of healthy adults using a new microinjection system: a 3-year randomised controlled safety and immunogenicity trial. BMC Med. 7, 13 (2009).
36. Arnou R, Eavis P, De Juanes Oardo et al. Immunogenicity, large scale safety and lot consistency of an intradermal influenza vaccine in adults aged 18-60 years. Hum. Vaccin. 6, 346-354 (2010).
37. Frenck RW Jr, Belshe R, Brady RC et al. Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults. Vaccine 5, 29(34), 5666-5674 (2011).
38. Holland D, Booy R, De Looze F et al. Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J. Infect. Dis. 198, 650-658 (2008).
39. Arnou R, Icardi G, De Decker M et al. Intradermal influenza vaccine for older adults: a randomized controlled multicenter Phase 3 study. Vaccine 27, 7304-7312 (2009).
40. Van Damme P, Arnou R, Kafeja F et al. Evaluation of non-inferiority of intradermal versus adjuvanted seasonal influenza vaccine using two serological techniques: a randomised comparative study. BMC Infect. Dis. 10, 134 (2010).
41. Morelon E, Noble CP, Daoud S et al. Immunogenicity and safety of intradermal influenza vaccination in renal transplant patients who were non-responders to conventional influenza vaccination. Vaccine 28(42), 6885-6890 (2010).
42. Van Damme P, Oosterhuis-Kafeja F, Van der Wielen M, Almagor Y, Sharon O, Levin Y. Safety and efficacy of a novel microneedle device for dose sparing intradermal influenza vaccination in healthy adults. Vaccine 27(3), 454-459 (2009).
43. Reygrobellet C, Viala-Danten M, Meunier J, Weber F, Nguyen VH. Perception and acceptance of intradermal influenza vaccination: patient reported outcomes from Phase 3 clinical trials. Hum. Vaccin. 6(4), 336-345 (2010).
44. Eizenberg P, Booy R, Naser N, Mason G, Stamboulian D, Weber F. Acceptance of Intanza® 9 μg intradermal influenza vaccine in routine clinical practice in Australia and Argentina. Adv. Ther. 28(8), 640-649 (2011).
45. Beguin C, Boland B, Ninane J. Health care workers: vectors of influenza virus? Low vaccination rate among hospital health care workers. Am. J. Med. Qual. 13, 223-227 (1998). (Pubitemid 128449351)